Report #2873009

Overview

Sex

Female

Age

36 yrs

State

CO

Recovered

Unknown

Vaccinated

Sep 1, 2025

Onset

Nov 7, 2025

Days to onset

67

Hospital days

—

Symptoms (2)

Symptom narrative

1st dose received during pregnancy; Boostrix extra dose in a patient with 34 weeks of pregnancy; Boostrix extra dose in a patient with 34 weeks of pregnancy; This non-serious prospective pregnancy case was reported by a other health professional via call center representative and described the occurrence of vaccine exposure during pregnancy in a 36-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number SN9L9, expiry date 28-NOV-2027) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) for prophylaxis. On 07-NOV-2025, the patient received the 2nd dose of Boostrix. In SEP-2025, the patient received the 1st dose of Boostrix. On 07-NOV-2025, an unknown time after receiving Boostrix and not applicable after receiving Boostrix, the patient experienced extra dose administered (Verbatim: Boostrix extra dose in a patient with 34 weeks of pregnancy). On an unknown date, the patient experienced vaccine exposure during pregnancy (Verbatim: 1st dose received during pregnancy) and vaccine exposure during pregnancy (Verbatim: Boostrix extra dose in a patient with 34 weeks of pregnancy). The outcome of the vaccine exposure during pregnancy, vaccine exposure during pregnancy and extra dose administered were not applicable. Pregnancy exposure: Pregnancy Exposure (Boostrix): To mother in third trimester Pregnancy Exposure (Boostrix): Trimester unknown Pregnancy Outcome: Pregnancy was ongoing This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 07-NOV-2025 A practice manager asked how to proceed with a pregnant patient that received one dose of Boostrix in September 2025 and again another dose. The reporter consented to follow up.